Selinexor Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as KARYOPHARM THERAPS. It is marketed under 1 brand name, including XPOVIO. Available in 5 different strengths, such as 20MG, 40MG, 50MG and others, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"103371","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"a22fd730a5564b91b887","publication_number":"US9714226B2","cleaned_patent_number":"9714226","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2017-07-25","legal_status":"Granted"} US9714226B2 Molecular Formulation 25 Jul, 2017 Granted 26 Jul, 2032
{"application_id":"103373","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"a22fd730a5564b91b887","publication_number":"US10544108B2","cleaned_patent_number":"10544108","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2020-01-28","legal_status":"Granted"} US10544108B2 28 Jan, 2020 Granted 26 Jul, 2032
{"application_id":"103374","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"a22fd730a5564b91b887","publication_number":"US11034660B2","cleaned_patent_number":"11034660","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2021-06-15","legal_status":"Granted"} US11034660B2 15 Jun, 2021 Granted 26 Jul, 2032
{"application_id":"103378","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"e57058901e7a4c408d2b","publication_number":"US11787771B2","cleaned_patent_number":"11787771","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2023-10-17","legal_status":"Granted"} US11787771B2 17 Oct, 2023 Granted 26 Jul, 2032
{"application_id":"242166","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"","publication_number":"US12291508B2","cleaned_patent_number":"12291508","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2025-05-06","legal_status":"Granted"} US12291508B2 06 May, 2025 Granted 26 Jul, 2032
{"application_id":"103296","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"a22fd730a5564b91b887","publication_number":"US9079865B2","cleaned_patent_number":"9079865","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-26","publication_date":"2015-07-14","legal_status":"Granted"} US9079865B2 14 Jul, 2015 Granted 26 Jul, 2032
{"application_id":"103368","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"a22fd730a5564b91b887","publication_number":"US8999996B2","cleaned_patent_number":"8999996","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-07-03","publication_date":"2015-04-07","legal_status":"Granted"} US8999996B2 Molecular Formulation 07 Apr, 2015 Granted 03 Jul, 2033
{"application_id":"103412","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"09e9f3fec1064940b326","publication_number":"US11807629B2","cleaned_patent_number":"11807629","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2023-11-07","legal_status":"Granted"} US11807629B2 Molecular 07 Nov, 2023 Granted 14 Aug, 2035
{"application_id":"103391","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"55af76720db64191a6a8","publication_number":"US10519139B2","cleaned_patent_number":"10519139","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2019-12-31","legal_status":"Granted"} US10519139B2 Molecular Formulation 31 Dec, 2019 Granted 14 Aug, 2035
{"application_id":"116945","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"56bfec65271a47aaa1ac","publication_number":"US11746102B2","cleaned_patent_number":"11746102","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2023-09-05","legal_status":"Granted"} US11746102B2 05 Sep, 2023 Granted 14 Aug, 2035
{"application_id":"116939","ingredient":"SELINEXOR","trade_name":"XPOVIO","family_id":"56bfec65271a47aaa1ac","publication_number":"US11753401B2","cleaned_patent_number":"11753401","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2023-09-12","legal_status":"Granted"} US11753401B2 Formulation 12 Sep, 2023 Granted 14 Aug, 2035

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Selinexor

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.